News

The GNHA assembled this summer to discuss the current VMS landscape, concluding it is riddled with inconsistent messages and misconceptions that ultimately may confuse both healthcare professionals and

ChromaDex’s NIAGEN™ is the first and only commercially available form of nicotinamide riboside (NR), a naturally occurring no-flush vitamin B3 metabolite found in milk. Published research has shown

In this analysis, survival in patients with HPP at high risk of death who were treated with asfotase alfa for up to five years was significantly improved (89%

Based on the data contained in the NDA for Saxenda, the FDA asked the panel members to discuss whether Novo Nordisk has provided adequate evidence to establish the

The Committee’s recommendation will be considered by the FDA in its review of the company’s Biologics License Application (BLA) for Natpara, which has a Prescription Drug User Fee

Tecemotide was being assessed in the Phase III START2, START and INSPIRE trials to treat unresectable, locally advanced Stage III NSCLC. In 2007, the company received the exclusive

The new joint venture (JV) will be known as TIPR-HUYA Advancing Innovative Medicines (TIPR-HUYA-AIM). Under the deal, the two firms will share equally in decision-making regarding product development

Preeclampsia is one of the most common complications of pregnancy and it leads to increased risk of maternal mortality, perinatal fetal mortality, fetal pre-maturity, or even the need

SYN-005 is being developed through Synthetic Biologics’ exclusive channel collaboration with Intrexon (XON) and academic researchers at the University of Texas at Austin to target and neutralize the